Paper32100240
The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.
Sammons S and 2 others. Drugs Aging, 2020. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease. Papers, record 32100240. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32100240
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Aromatase Inhibitors | Major topic |
| Breast Neoplasms | Major topic |
| Receptors, Cell Surface | Major topic |
| Tamoxifen | Major topic |
| Aged | |
| Chemotherapy, Adjuvant | |
| Combined Modality Therapy | |
| Early Detection of Cancer | |
| Female | |
| Geriatric Assessment | |
| Humans | |
| Neoplasm Staging | |
| Practice Guidelines as Topic | |
| Erb-b2 Receptor Tyrosine Kinases |
Source PubMed
References167
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1746054 | Response of primary breast cancer to tamoxifen alone in elderly women. | Tumori | 1991 | https://conductscience.org/library/papers/1746054 | PubMed |
| 2 | 21371853 | A population-based validation of the prognostic model PREDICT for early breast cancer. | Eur J Surg Oncol | 2011 | https://conductscience.org/library/papers/21371853 | PubMed |
| 3 | 2895214 | Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. | Lancet | 1988 | https://conductscience.org/library/papers/2895214 | PubMed |
| 4 | 14588130 | Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients. | J Womens Health (Larchmt) | 2003 | https://conductscience.org/library/papers/14588130 | PubMed |
| 5 | 26884586 | Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/26884586 | PubMed |
| 6 | 29932846 | Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology Summary. | J Oncol Pract | 2018 | https://conductscience.org/library/papers/29932846 | PubMed |
| 7 | 24197662 | Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93. | Breast Cancer Res Treat | 2013 | https://conductscience.org/library/papers/24197662 | PubMed |
| 8 | 27992272 | Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/27992272 | PubMed |
| 9 | 12039943 | Association of tamoxifen and uterine sarcoma. | J Clin Oncol | 2002 | https://conductscience.org/library/papers/12039943 | PubMed |
| 10 | 14513434 | Pharmacokinetics of third-generation aromatase inhibitors. | Semin Oncol | 2003 | https://conductscience.org/library/papers/14513434 | PubMed |
| 11 | 15591335 | A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15591335 | PubMed |
| 12 | 22152852 | The 2011 EBCTCG polychemotherapy overview. | Lancet | 2012 | https://conductscience.org/library/papers/22152852 | PubMed |
| 13 | 12538506 | National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. | Clin Cancer Res | 2003 | https://conductscience.org/library/papers/12538506 | PubMed |
| 14 | 26277113 | A pharmacist-led medication assessment used to determine a more precise estimation of the prevalence of complementary and alternative medication (CAM) use among ambulatory senior adults with cancer. | J Geriatr Oncol | 2015 | https://conductscience.org/library/papers/26277113 | PubMed |
| 15 | 23949153 | The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. | Br J Cancer | 2013 | https://conductscience.org/library/papers/23949153 | PubMed |
| 16 | 17470740 | Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. | J Natl Cancer Inst | 2007 | https://conductscience.org/library/papers/17470740 | PubMed |
| 17 | 22318280 | Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. | JAMA | 2012 | https://conductscience.org/library/papers/22318280 | PubMed |
| 18 | 30787125 | NCCN Guidelines Insights: Breast Cancer, Version 3.2018. | J Natl Compr Canc Netw | 2019 | https://conductscience.org/library/papers/30787125 | PubMed |
| 19 | 29128896 | Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer. | Breast Cancer Res Treat | 2018 | https://conductscience.org/library/papers/29128896 | PubMed |
| 20 | 10615079 | Underrepresentation of patients 65 years of age or older in cancer-treatment trials. | N Engl J Med | 1999 | https://conductscience.org/library/papers/10615079 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40004963 | A Systematic Review of Vitamin D Supplementation in Oncology: Chance of Science or Effectiveness? | Nutrients | 2025 | https://conductscience.org/library/papers/40004963 | PubMed |
| 34893669 | Epigenome association study for DNA methylation biomarkers in buccal and monocyte cells for female rheumatoid arthritis. | Sci Rep | 2021 | https://conductscience.org/library/papers/34893669 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CDK4 | 1019 | PubTator's text mining | https://conductscience.org/library/genes/1019 | NCBI Gene |
| CDK6 | 1021 | PubTator's text mining | https://conductscience.org/library/genes/1021 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32100240
GET https://conductscience.org/api/papers/v1/32100240/references?page=2